Contact Us
Contact Us
Blog Posts

Introducing Stefan Bauer, Senior Director, Analytical Development

In today’s blog, we are pleased to introduce Stefan Bauer, Senior Director, Analytical Development. Stefan brings nearly two decades of analytical chemistry expertise to Antheia, with a career that took him from food chemistry in Germany to leading high-performing labs across the U.S. biotech industry. We sat down with Stefan to learn about his journey to Antheia, how he balances hands-on lab work with leading a team, and his goals for the year ahead.

Tell us about your background and career journey. You started out in food chemistry in Germany before moving into biotech in the U.S. What drew you to this field, and how did that early training shape your approach to analytical chemistry?

Food chemistry in Germany is essentially analytical chemistry. It covers everything food-related, but also consumer goods like clothing and toys. In principle, it’s anything that comes into contact with the human body, except pharmaceuticals, which is its own field. The core question is always the same: what components or chemicals are present, and in what quantity? I was exposed to a wide range of analytical techniques designed to answer that question. Unlike other branches of chemistry, it’s a field that friends and family could actually relate to and understand.

My path to becoming a state-certified food chemist included training at a state lab, which also covered food law. While I was there, a new lab was built out for meat profiling and authentication, which is accomplished through DNA testing, a method I hadn’t worked with before. It opened my eyes to a new way of solving analytical problems.

I wanted to deepen my knowledge of molecular biology and understand the possibilities of this newer technology, which led me to a postdoc at Stanford where I learned PCR, sequencing, DNA analysis, cloning, and protein expression. I combined those skills with analytical techniques to characterize an enzymatic toolkit for analyzing plant cell wall carbohydrates.

This brought me to the Energy Biosciences Institute at Berkeley, which focused on generating biofuels through strain engineering and chemical catalysis. They needed a core analytical facility manager who understood the chemistry and could speak the language of the molecular biology team. That was my entry point into biotech.

From there, I moved into a series of fermentation-focused biotech startups, including Zymergen, where I spent seven years building out and leading the R&D analytical chemistry side of the high-throughput strain screening platform. Those experiences allowed me to apply my analytical background to everything from engineered microbial strains to alternative proteins. In hindsight, analyzing complex food matrices had uniquely prepared me for analyzing complex biotech samples like fermentation broth. Many food products are themselves fermentation-derived, so the shift felt less like a deviation and more like a natural continuation. I simply enjoy applying chromatography and mass spectrometry. Where the sample comes from matters less to me than the technique itself.

What made you decide to join Antheia, and how does the work here compare to the systems you’ve analyzed in the past?

Antheia checked many of my boxes. I enjoy working for a smaller company because decision-making tends to be faster and less bureaucratic. You’re also close to everyone, and you see the immediate impact of what you’re doing.

My job now is probably less high-throughput than past positions, but it still involves a variety of interesting analytical techniques. The pathways leading to our products are complex, and every round of strain engineering can affect the metabolic profile, which needs to be monitored closely. So I’m not worried about the job becoming boring anytime soon.

Having learned from past experiences in the startup world, I was also drawn to the fact that Antheia already has a product at commercial stage. Seeing the full pipeline of products to come was the final piece for me. It’s both the day-to-day work and the future we’re working toward that make this an interesting job.

As Senior Director of Analytical Development, what does your day-to-day look like? How do you balance staying hands-on with leading the team?

My ultimate responsibility is to make sure we have the resources and means to support the DSP, fermentation, and biology teams. As a team leader, I need to identify the gaps we have and work to fill them. In practice, that means knowing the capabilities of my team members, including their individual strengths and growth opportunities. It also means figuring out how to tap into their interests and fully develop their potential.

Being hands-on makes it easier to lead a team, in my view. You’ll often find me at the bench or in front of an instrument in the lab. I believe in leading by example and want to earn the team’s trust, especially in my technical knowledge. Practically, it also gives me a better sense of how long certain steps take, which matters a lot for resource and timeline planning.

We’re a smaller team, which means all hands on deck at all times. We’re constantly asked to develop new methods and if my team is busy with other projects, I’ll jump in for method development or sample analysis. Sometimes I’ll start the proof of concept work and hand it over to a team member to finish and other times I’m able to see it through completely. So it’s a mix of developing new methods and jumping in wherever it’s needed most, whether that means routine analysis or something more novel. 

What do you look for when building a team, and how would you describe your leadership philosophy?

I believe the most valuable team members are the ones who not only have high integrity and take strong ownership of their work, but also bring curiosity and stay open to doing things differently. I remind my team that they should always question how we do things in the lab and ask why decisions are made a certain way. Hearing everyone’s questions and welcoming all perspectives often leads to a better outcome. We all have our own weaknesses, but as a team, we can fill each other’s gaps.

What are you hoping to accomplish in your first year at Antheia, and what does success look like for your team down the road?

We’ve successfully demonstrated that our routine targeted analysis is achieved with high precision and accuracy. Now we need to focus more on identifying unknown compounds in our samples. Our metabolic pathways are complex, and combined with the DSP isolation steps, there’s a risk that unexpected compounds are produced along the way. When that happens, we need to identify them so that DSP can design strategies to remove them, or biology can find ways to prevent their production.

The challenge is that many of these compounds can’t be identified using commercial or public databases, and the published literature doesn’t always have answers either. We recently brought a high-resolution mass spectrometer online in the lab, and we’re building out our own reference library to help close that gap over time.

I also hope to bring in better software tools for a technique called discriminant analysis, which helps detect subtle differences between samples. That would speed up our ability to identify on the changes that matter most. Beyond small molecules, there’s also the potential presence of larger compounds, like proteins, carbohydrates, or lipids, and we’re working on making the analysis of those a routine part of our workflow as well.

I’m also keeping an eye on how AI will play into our work. There’s real potential in areas like pattern recognition. For example, training a model to predict the mass spectrum of an unknown compound based on similar, already-identified ones. It’s early days for us, and we’d need more data before those tools are reliable, but it’s a direction I’d like to explore.

Another goal is bringing more automation into the lab. As Antheia grows and takes on more projects, our current approach to sample prep will also need to scale. Automating repetitive work will free up the team to focus on method development and improvement.

Ultimately, a successful analytical development team keeps delivering high-quality data with a quick turnaround, while also responding quickly to issues so that DSP, fermentation, and biology can adjust their processes accordingly.

Tell us about your life outside of work.

I have two daughters, two dogs (often four, when we dog sit for a friend), and a rabbit. And a big garden that needs maintenance, so I can’t really complain about getting bored in my spare time.

I usually spend my commute reading. I’m also drawn to certain historical epochs, especially the early 17th to mid-18th century, including civilian and military life, architecture, and clothing. That interest shows up in a large collection of custom-built figures based on Playmobil, a German toy of my childhood. The collection keeps growing whenever new parts become available. It’s a hobby I return to whenever I have the time.

Follow Antheia on LinkedIn 

Adam Takos, PhD

Head of Drug Innovation and Managing Director, Singapore

Adam has spent two decades driven by a fascination with how we can harness biology to solve complex challenges. His journey has been a rewarding evolution—from making fundamental discoveries in plant specialized metabolism to leading industrial programs in metabolic engineering and drug discovery. Beyond the technical work, Adam is an advocate for “no-fear-of-failure” team cultures. Having worked across three countries, he values the diverse perspectives that drive innovation and help us turn ambitious research into practical, life-saving solutions.

Chris Savile, PhD

Head of Business Development and Partnerships

Chris has spent the past 20 years focused on the development and commercialization of biomanufacturing processes across multiple sectors and has spent his recent career focused on identifying high-value commercial opportunities and building strategic partnerships in pharma, food, and health and wellness. Prior to joining Antheia, he was CEO at Willow Biosciences, executive director, commercial operations at Intrexon, and associate director, business development and senior scientist, R&D at Codexis. Chris holds a PhD in organic chemistry from McGill University.

Dr. Stefan Bauer

Head of Analytical Development

Stefan is a senior biotechnology leader in analytical chemistry and a passionate scientific and technical expert in analytical methods and principles, especially chromatography and mass spectrometry, using an extensive range of instrumentations for a variety of analytes in complex matrices, such as microbial fermentations. With a 20-year career-long commitment to high quality standards, focusing on optimizing and simplifying workflows, he excels at developing high-throughput methods that drive efficiency, cost savings, operational excellence, and scientific innovation. Previously, he led the bioanalytical teams at UC Berkeley, Zymergen, Perfect Day, Novonutrients, Inscripta, and Manus.

Andrew Saarni

Head of Fermentation Process Development & Scale-Up

Andrew is a strategic bioprocess leader with over a decade of experience guiding fermentation process development and scale-up efforts from early-stage R&D through commercial deployment for small molecules, proteins, and now, vital alkaloid medicines. He has a proven track record of aligning technical execution with business strategy, driving technology transfer and manufacturing readiness at domestic and international CDMOs, and building fermentation infrastructures that deliver precision, throughput, and reproducibility. Before Antheia, he was Director of Fermentation at Geltor and a Senior Fermentation Engineer at Geno. He currently leads Antheia’s global fermentation scale-up efforts to secure next-generation supply chains for critical medicines.

Richard Sherwin

Head of Commercialization

Richard is an industry veteran with more than 30 years of experience in the KSM, API, and intermediate markets. He is responsible for leading the commercialization and revenue generation for Antheia’s robust pipeline of products. Richard brings an exceptional track record of leading international sales teams, driving revenue growth, building strategic partnerships, and delivering innovative products to market, including ANDA and NDA developments. Richard led commercial efforts at some of the leading global pharmaceutical companies and most recently, built his own consultancy business advising a range of clients, including $1B divisions of major multinationals.

Appropriate regulatory submissions will be prepared and submitted to support Antheia’s customers who need to reference and access necessary process-related information.

Yihui Zhu, PhD

Head of Fermentation

Yihui leads the fermentation team at Antheia. With over 25 years of hands-on experience in the field, he brings in-depth knowledge and expertise in microbial metabolism and fermentation process development. He is also skilled in developing comprehensive fermentation data collection, analysis, and visualization systems. Prior to joining Antheia, he served as a fermentation lead at Intrexon and Codexis where he successfully built fermentation labs and teams and led multiple biofuel and biochemical projects to reach stretch milestones and tech transfer. Yihui is passionate about the potential of fermentation and is dedicated to advancing the field through innovative research and development.

Audrey Wang

Head of Financial Planning and Analysis

Audrey leads financial planning and analysis at Antheia. With an MBA from Washington University in St. Louis, Audrey is passionate about leveraging financial analysis, digital technology, and data analytics to guide companies in making optimal investments and strategic business decisions. Audrey has a decade of experience in helping companies solve unique problems and creating long-term impact with unconventional approaches. Before joining Antheia, she was at Vir Biotechnology and Merck where she led various FP&A workstreams, including investment valuation, asset prioritization, and manufacturing sites operation finance support. Audrey completed CFA Level II and passed the U.S. CPA exam in 2011.

Antonij Tjahjadi, CPA

Head of Accounting

Antonij Tjahjadi leads accounting at Antheia and holds active CPA license. He joined Antheia with more than 20 years of experience in corporate accounting, bringing deep expertise in ramping up accounting operations for start-up companies, SEC reporting/technical accounting, and SOX implementation efforts. Before joining Antheia, he held various leading roles in both public and private company settings, including directing accounting functions at Ambys Medicines, where he successfully implemented Netsuite with Point Purchasing integration and set up various accounting policies and processes, and played a key role in the initial public offering of Nutanix, Inc.

Ken Takeoka

Head of Biology

Ken leads the Biology team at Antheia, which incorporates both strain and protein engineering functions. He has more than 16 years of experience in the synthetic biology field, working with leading companies, including Amyris and Novartis. One of his passions is molecular biology tool development and he previously worked to build the foundation for the automated strain engineering pipeline at Amyris. At Novartis, he modernized the molecular biology techniques and established a platform to model mechanisms of antibiotic resistance in a range of organisms.

Suzanne Sato

Head of Downstream Processing

Suzy leads downstream chemistry processes at Antheia. She has 19 years of experience in process development, including route development through synthetic chemistry and scale-up of small molecule APIs for GPCR targets under cGMP for Phase I-III trials. Before joining Antheia, Suzy led a full DSP team at Amyris where she successfully pivoted developments from biofuels hydrocarbon products to pharmaceutical intermediate, flavor, fragrance and nutraceutical products. She led a team that scaled 11 products and took five products to commercial manufacturing.

Farrah Pulce, PMP

Head of Project Management

Farrah leads program and project management at Antheia. She has over 20 years of experience leading program and project management, operations, and engineering for companies across the CPG, aerospace, and automotive industries. Prior to joining Antheia, Farrah implemented and led the sustaining program management team at Impossible Foods. She also led product operations, project management, and cost optimization at Blue Bottle Coffee and Tyson Foods to develop and commercialize new products. As a certified project management professional (PMP), Farrah has a proven record of successful project delivery, improving project management practices, and building collaborative teams.

Jordyn Lee

Head of Communications

Jordyn leads communications and external affairs at Antheia. She brings a decade of multidisciplinary communications experience in helping companies make complex science and technology accessible to broad audiences, all while maintaining technical accuracy and integrity. She has a passion for visionary storytelling and translating impact across the entire communications ecosystem – her work has spanned from public relations to corporate communications to marketing. Jordyn has served as an advisor to a number of different life sciences companies and most recently led corporate communications at Amyris.

Ben Kotopka, PhD

Head of Data Science

As Head of Data Science at Antheia, Ben manages in-house software development and external partnerships for storing and interpreting research data, executing bioinformatics analyses, and streamlining business processes. Prior to Antheia, Ben worked as an academic researcher at the intersection of machine learning, bioinformatics, and synthetic biology. Following this, as an entrepreneur and consultant, he developed and deployed data science solutions for biotechnology applications ranging from metabolomics-driven compound discovery to MRI segmentation.

Guerin Kob

Head of Supply Chain

Guerin is responsible for leading the design, development, management and improvement of Antheia’s end-to-end global supply chain. He has over 15 years of experience leading high-performing supply chain and procurement teams at leading biotechnology and specialty chemical companies, with extensive experience in process development and end-to-end supply chain optimization. Prior to joining Antheia, Guerin served as Senior Director of Global Supply Chain for Sumitomo Chemical’s biotechnology division with Valent Biosciences, where he led the end-to end supply chain including procurement, logistics and distribution, integrated business planning, materials management, customer service, and supply planning functions globally.

Eric d'Esparbes

Chief Financial Officer

Eric is a seasoned executive with 30 years of experience serving as the Chief Financial Officer for both private and public companies across various industries, including pharmaceuticals, biotechnology, diagnostics, and energy. He has successfully built and managed finance organizations for companies with a broad international footprint and annual sales of up to $3.5 billion. Eric has a proven track record in investor relations, capital raising to support organic growth and strategic partnerships/M&A, optimizing capital structures, and managing IPO processes, including transitions from private to public companies.

Jesse Ahrendt

Head of Quality Assurance and Regulatory Affairs

Jesse has more than 25 years of experience in regulatory affairs, quality systems, manufacturing quality, and regulated industries, ranging from early- to late-stage pharmaceuticals, biomanufacturing, consumer care, and medical devices. He has supported global product launches and the underlying quality supply chain components in industries that require strict adherence to internationally accepted quality standards. Before Antheia, he led quality efforts at Zymergen and Sandoz, and supported many global pharmaceutical companies during his time in Biotech Consulting at NSF International, all to bring quality to the forefront in manufacturing, standardize global processes, and support customer regulatory requirements.

Heidi Pucel

Chief People Officer

Heidi is a results-driven human resources executive and HR business partner who leverages decades of experience in empowering, motivating, and inspiring to drive transformation within high-performing and rapidly-growing workforces. A certified executive coach and passionate advocate for people-oriented solutions, Pucel serves as a partner to executive teams to design programs that support employee development, engagement, and recruitment and retention. Pucel most recently served as Chief People Officer for Countsy, where she worked as an interim HR executive for clients in the biotechnology and software industries, such as Ceribell and Tune Therapeutics.

Zack McGahey

Chief Operating Officer

Zack is a leading executive in operations management, specializing in bioprocess engineering and manufacturing management. He has over 20 years of experience leading manufacturing functions for companies across the pharmaceutical, synthetic biology, diagnostics, and automotive industries. Before joining Antheia, Zack was VP of manufacturing and capex project management at Zymergen. He also gained experience managing commercial scale facilities operations for Tesla, where he was responsible for managing 10 million square feet of factory, lab and warehouse space during the Model 3 ramp.

Kristy Hawkins, PhD

Co-Founder & CSO

Kristy has over 20 years of experience in the field of synthetic biology, focusing on yeast metabolic engineering for the production of small molecules. She did the founding work on the benzylisoquinoline alkaloid pathway during her graduate studies and gained valuable industry experience at Amyris and Lygos. Kristy is an expert in tool development, high-throughput screening, and host strain and heterologous pathway engineering.

Christina Smolke, PhD

Co-Founder & CEO

Christina is a pioneer in synthetic biology and metabolic engineering, where she has over 20 years of experience. As Professor of Bioengineering and Chemical Engineering at Stanford University, her laboratory led the breakthrough research to engineer baker’s yeast to produce some of the most complex and valuable medicines known. Under her leadership, Antheia’s advanced biosynthesis platform enables new possibilities for drug discovery and efficient, sustainable, transparent, and on-demand drug manufacturing at scale. Her vision and accomplishments have garnered numerous awards, including the Chan-Zuckerberg Biohub Investigator, NIH Director’s Pioneer Award, Nature’s 10, Novozymes Award for Excellence in Biochemical Engineering, and TR35 Award.

Antheia Appoints Dr. Chris Savile as VP of Business Development and Partnerships

Appropriate regulatory submissions will be prepared and submitted to support Antheia’s customers who need to reference and access necessary process-related information.